HomeCompareBAX vs FITB

BAX vs FITB: Dividend Comparison 2026

BAX yields 2.28% · FITB yields 3.45%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FITB wins by $169.5K in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
FITB
FITB
● Live price
3.45%
Share price
$44.68
Annual div
$1.54
5Y div CAGR
45.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$190.1K
Annual income
$82,140.41
Full FITB calculator →

Portfolio growth — BAX vs FITB

📍 FITB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXFITB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + FITB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
FITB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
FITB
Annual income on $10K today (after 15% tax)
$292.97/yr
After 10yr DRIP, annual income (after tax)
$69,819.35/yr
At 15% tax rate, FITB beats the other by $69,810.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + FITB for your $10,000?

BAX: 50%FITB: 50%
100% FITB50/50100% BAX
Portfolio after 10yr
$105.4K
Annual income
$41,075.33/yr
Blended yield
38.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FITB right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
FITB
Analyst Ratings
1
Strong
26
Buy
22
Hold
2
Sell
Consensus: Buy
Price Target
$56.90
+27.4% upside vs current
Range: $50.00 — $61.00
Altman Z
0.2
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
FITB buys
0
No recent congressional trades found for BAX or FITB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXFITB
Forward yield2.28%3.45%
Annual dividend / share$0.36$1.54
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%45.8%
Portfolio after 10y$20.6K$190.1K
Annual income after 10y$10.26$82,140.41
Total dividends collected$602.00$157.8K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldBuy
Analyst price target$19.75$56.90

Year-by-year: BAX vs FITB ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrFITB PortfolioFITB Income/yrGap
1← crossover$10,866$166.33$11,203$502.53$337.00FITB
2$11,750$123.31$12,754$767.11$1.0KFITB
3$12,664$90.97$14,837$1,190.02$2.2KFITB
4$13,617$66.89$17,762$1,886.34$4.1KFITB
5$14,619$49.07$22,082$3,077.09$7.5KFITB
6$15,679$35.94$28,840$5,212.79$13.2KFITB
7$16,802$26.30$40,136$9,277.03$23.3KFITB
8$17,998$19.23$60,538$17,592.13$42.5KFITB
9$19,272$14.05$100,932$36,156.20$81.7KFITB
10$20,631$10.26$190,137$82,140.41$169.5KFITB

BAX vs FITB: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

FITBFinancials

Fifth Third Bancorp operates as a diversified financial services company in the United States. The company's Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and cash management, foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers. Its Branch Banking segment provides a range of deposit and loan products to individuals and small businesses. This segment offers checking and savings accounts, home equity loans and lines of credit, credit cards, and loans for automobiles and personal financing needs, as well as cash management services for small businesses. The company's Consumer Lending segment engages in direct lending activities that include origination, retention, and servicing of residential mortgage and home equity loans or lines of credit; and indirect lending activities, including loans to consumers through correspondent lenders and automobile dealers. Fifth Third Bancorp's Wealth & Asset Management segment provides various investment alternatives for individuals, companies, and not-for-profit organizations. It offers retail brokerage services to individual clients; and broker dealer services to the institutional marketplace. This segment also provides wealth planning, investment management, banking, insurance, and trust and estate services; and advisory services for institutional clients comprising middle market businesses, non-profits, states, and municipalities. As of December 31, 2021, the company operated 1,117 full-service banking centers and 2,322 ATMs in Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, North Carolina, and South Carolina. Fifth Third Bancorp was founded in 1858 and is headquartered in Cincinnati, Ohio.

Full FITB Calculator →
📬

Get this BAX vs FITB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.